This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Rv51 | |
|---|---|
| Name | Rv51 |
Rv51 is a designation used in scientific literature to refer to a specific gene product implicated in studies of Mycobacterium tuberculosis, bacterial pathogenesis, and comparative genomics across the Actinobacteria phylum. It appears in discussions linking classical microbiology investigations with modern techniques in genome sequencing, proteomics, and structural biology, and it has been considered in contexts ranging from vaccine research to antimicrobial resistance surveillance.
Rv51 has been mapped within genomic annotations emerging from large-scale projects such as the H37Rv reference strain sequencing and comparative analyses involving Mycobacterium bovis, Mycobacterium smegmatis, and other members of the Mycobacterium tuberculosis complex. Researchers reference Rv51 in studies employing RNA-seq, mass spectrometry, and X-ray crystallography to integrate information about transcriptional regulation, protein expression, and three-dimensional structure. Interest in Rv51 spans groups working on host–pathogen interactions, innate immunity models (including macrophage infection assays), and translational initiatives aiming for new diagnostics and therapeutics.
The identifier Rv51 emerged from the landmark Mycobacterium tuberculosis H37Rv genome project led by investigators using technologies developed by entities like the Sanger Institute and centers participating in the Human Genome Project era. Subsequent annotation rounds incorporated comparative work involving sequencing efforts from institutions such as Centers for Disease Control and Prevention, Broad Institute, and national reference laboratories. Functional characterization traces through classic genetic studies using techniques pioneered by scientists affiliated with Robert Koch-inspired bacteriology traditions, later augmented by molecular methods popularized in labs associated with Pierre Chambon-style cloning and Fred Sanger sequencing pipelines.
Characterization of the Rv51-encoded polypeptide (when translated) relies on tools from bioinformatics and experimental platforms such as liquid chromatography–mass spectrometry and nuclear magnetic resonance spectroscopy. Computational predictions often reference homology to proteins cataloged in databases curated by groups like the UniProt Consortium and structural templates from the Protein Data Bank. Predicted features may include conserved motifs observed among proteins annotated in taxa represented by Corynebacterium diphtheriae, Nocardia asteroides, and other Actinomycetales, with biochemical properties inferred via comparison to characterized enzymes studied in labs at institutions like Harvard Medical School and Stanford University.
Functional hypotheses about Rv51 activity are shaped by experiments utilizing genetic knockouts, complementation assays, and biochemical interrogation performed in facilities such as those of the Wellcome Trust and academic centers conducting infection models referencing mouse and guinea pig systems. Proposed mechanisms invoke interaction networks with known Mycobacterium tuberculosis pathways examined in the context of targets validated by groups investigating drugs like isoniazid, rifampicin, and streptomycin. Studies also integrate signaling and regulatory frameworks framed by factors such as sigma factors and transcriptional regulators characterized in other bacterial systems documented by laboratories at Max Planck Institute and Pasteur Institute.
Work probing the biological role of Rv51 uses host models and cell lines developed in research programs at institutions like the National Institutes of Health and university hospitals. Investigations consider contributions to phenotypes such as intracellular survival within macrophages, modulation of host responses documented in cytokine profiling studies, and influences on virulence phenotypes assessed in genetic screens similar to those implemented in transposon sequencing projects run by the Wellcome Sanger Institute and the Broad Institute. Connections are often drawn to clinically relevant concerns addressed by organizations such as the World Health Organization and national tuberculosis control programs.
Detection strategies referencing Rv51 in diagnostic contexts employ molecular assays developed with platforms from companies and consortia like Cepheid, Roche Diagnostics, and academic core facilities implementing PCR, qPCR, and next-generation sequencing. Assays integrate probe design principles used in line probe assays and multiplex workflows similar to those evaluated by public health agencies including the Centers for Disease Control and Prevention. Proteomic detection leverages mass-spectrometry pipelines applied in clinical microbiology units at hospitals affiliated with Mayo Clinic and Johns Hopkins Hospital.
Rv51 has been considered as a candidate in exploratory work on antigen selection for subunit vaccine design and as a potential target in drug discovery programs conducted by pharmaceutical groups and academic consortia such as those involving the Bill & Melinda Gates Foundation and translational units at Imperial College London. Research applications include use as a marker in comparative genomics studies facilitated by resources like GenBank and annotation projects driven by the European Molecular Biology Laboratory. Continued investigation leverages collaborations spanning public health laboratories, university research centers, and industry partners focused on combating tuberculosis and related mycobacterial diseases.
Category:Mycobacterium tuberculosis genes